Patient-Friendly Explanation
Lixisenatide is an injectable medicine in the same GLP-1 family as many newer diabetes and weight-loss drugs. It is given once a day and works mainly after meals, slowing stomach emptying so you feel full sooner and your blood sugar rises less. It is used mostly for type 2 diabetes, with modest weight loss as a helpful effect.
Clinical Definition
Lixisenatide is a once-daily, short-acting GLP-1 receptor agonist used in type 2 diabetes, distinguished from longer-acting agents by its pronounced postprandial effect: it slows gastric emptying and stimulates glucose-dependent insulin secretion, targeting mealtime glucose excursions. Clinical trials report placebo-subtracted weight reductions of roughly 2 to 3 kg over 24 weeks, smaller than those seen with longer-acting GLP-1 receptor agonists, with a slightly higher rate of gastrointestinal side effects such as nausea and vomiting. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Why It Matters
Not all GLP-1 medicines produce the same amount of weight loss, and matching the drug to the patient’s glucose pattern matters. The doctors at NuLifeCare Singapore can explain whether a short-acting option like lixisenatide or a longer-acting medication better fits your blood sugar and weight goals.